Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

The effects of sorafenib treatment on the regulatory T cell (Treg) population

ABSTRACT: The effects of sorafenib treatment on the regulatory T cell (Treg) population

PROVIDER: PRJNA1176509 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR31093303_1.fastq.gz	Fastqsanger.gz
	SRR31093303_2.fastq.gz	Fastqsanger.gz
	SRR31093304_1.fastq.gz	Fastqsanger.gz
	SRR31093304_2.fastq.gz	Fastqsanger.gz
	SRR31093305_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 12

Similar Datasets

The effects of sorafenib treatment on the regulatory T cell (Treg) population

Project description:To investigate the impact of sorafenib treatment on gene expression in Treg cells, we performed RNA sequencing on Treg cells treated with sorafenib and on control Treg cells that were not treated with sorafenib. Specifically, our study focused on the expression of immune-suppressive related genes, and we observed an upregulation in the expression of Tgf-β1 (Transforming Growth Factor-β1), Prf1 (Perforin 1), Gzma (Granzyme A), and Il10 (Interleukin 10).

2025-01-05 | GSE280126 | GEO

The effects of sorafenib treatment on the CD4+T cell population

Project description:To investigate the impact of sorafenib treatment on gene expression in CD4+T cells, we performed RNA sequencing on CD4+T cells treated with sorafenib and on control CD4+T cells that were not treated with sorafenib. Specifically, our study focused on the expression of immune related genes, and we observed an downregulation in the expression of TCR genes.

2025-05-14 | GSE280959 | GEO

The effects of sorafenib treatment on the T helper cell (Th9) population

Project description:To investigate the impact of sorafenib treatment on gene expression in Th9 cells, we performed RNA sequencing on Th9 cells treated with sorafenib and on control Th9 cells that were not treated with sorafenib. Here, we found that the up regulation of genes about Il-9.

2025-05-14 | GSE280958 | GEO

The effects of sorafenib treatment on the CD4+T cell population

Project description:The effects of sorafenib treatment on the CD4+T cell population

| PRJNA1181542 | ENA

The effects of sorafenib treatment on the T helper cell (Th9) population

Project description:The effects of sorafenib treatment on the T helper cell (Th9) population

| PRJNA1181543 | ENA

The effects of sorafenib treatment on the Hep1-6 tumor tissue

Project description:This study aimed to investigate the transcriptomic changes in subcutaneous Hepa1-6 tumor tissues of mice following intraperitoneal administration of sorafenib, a tyrosine kinase inhibitor, versus a control solvent. Mice were injected with either sorafenib or the control solvent four times, according to the experimental design. After the treatment period, tumor samples were collected and subjected to RNA sequencing (RNA-seq) to analyze the gene expression profiles. The results from this RNA-seq analysis provide insights into the molecular mechanisms underlying the response of Hepa1-6 tumors to sorafenib treatment, potentially identifying novel therapeutic targets and biomarkers for hepatocellular carcinoma.

2025-01-05 | GSE283371 | GEO

T Regulatory Lymphocytes (Treg) Depletion for Cancer Treatment Efficacy and Safety Study

Project description:T regulatory lymphocytes were shown to be partly responsible for immune tolerance to cancer cells. In that respect these cells oppose to the mounting of an efficacious immune response needed to cure cancer. To treat advanced metastatic colorectal cancer, the investigators propose an immunotherapy consisting in autologous lymphocytes infusion depleted from T-regulatory cells, associated with a 5-day prior lymphoid-ablative chemotherapy associating cyclophosphamide (day 1 & 2) with fludarabine (day 1 to 5). To administer treatment and monitor chemotherapy safety, patients will be hospitalized for 3 weeks until complete recovery from chemotherapy. Patients will then be followed-up ambulatory for 9 months during which time they will be assessed for tumor size with computed tomography (CT) - scan (primary criteria).

| 2078724 | ecrin-mdr-crc

Interleukin-35-mediated induction of a novel regulatory T cell population

Project description:Regulatory T cells (Tregs) play a critical role in the maintenance of immunological self-tolerance. Naïve human or murine T cell treatment with the inhibitory cytokine IL35 induces a regulatory population, termed iTR35, that mediates suppression via IL35, but not IL10 or TGFβ, neither express nor require Foxp3, are strongly suppressive in five in vivo models, and exhibit in vivo stability. Treg-mediated suppression induces iTR35 generation in an IL35- and IL10-dependent manner in vitro, and in inflammatory conditions in vivo in Trichuris-infected intestines and within the tumor microenvironment, where they appear to contribute to the regulatory milieu. iTR35 may constitute a key mediator of infectious tolerance and may contribute to Treg-mediated tumor progression, and ex vivo-generated iTR35 may possess therapeutic utility. Five IL35-treated samples, in parallel with 5 control-treated samples, were compared to 3 Treg and 3 Tconv cell samples.

2010-09-18 | E-GEOD-24210 | biostudies-arrayexpress

AIM2 in regulatory T (Treg) cells restrains autoimmune diseases

Project description:The inflammasome initiates innate defense and inflammatory response by activating caspase-1 and pyroptotic cell death in myeloid cells1,2. It is comprised of an innate immune receptor/effector, pro-caspase-1 and a common adaptor molecule, ASC (apoptotic speck-containing protein with a CARD). Consistent with their pro-inflammatory function, inflammasome components including caspase-1, ASC and NLRP3, are known to exacerbate autoimmunity during experimental autoimmune encephalomyelitis (EAE) by enhancing IL-1 and IL-18 secretion in myeloid cells3-6. Here we show an unexpected function of a DNA-binding inflammasome effector, AIM2 (Absent in Melanoma 2)7-10, in restraining autoimmunity by performing EAE in both whole body and Treg-specific deletion of Aim2–/– mice. AIM2 is highly expressed by human and mouse Treg cells and it is essential to attenuate EAE. RNA-seq, biochemical and metabolic analyses revealed that AIM2 attenuates mTOR, Myc and immune-metabolic functions in both Treg cells isolated in vivo and Treg cells induced in vitro with TGF-. Importantly, we found AIM2 physically interacted with RACK1 in Treg cells to facility the PP2A/RACK1/Akt-mTOR signaling, which is identified as a central component downstream of AIM2 that controls Treg cell function and stability. While AIM2 is generally accepted as an inflammasome effector in myeloid cells, this report reveals a previously unappreciated T cell-intrinsic role of AIM2 in maintaining Treg cell function to restrain autoimmunity. This is achieved by diminishing Akt-mTOR signaling to regulate Treg stability under inflammation, and altering immune-metabolism in Treg cells.

2021-01-27 | PXD018638 | Pride

Deconstructive SCNT reveals heterogeneity within Treg population

Project description:Deconstructive SCNT reveals heterogeneity within Treg population

| PRJNA383046 | ENA